BT-267, an LRRK2 inhibitor being developed by Brenig Therapeutics as a treatment for Parkinson’s disease, has reached…
Articles by Andrea Lobo
The American Parkinson Disease Association (APDA) is urging U.S. Department of Health and Human Services (HHS) Secretary Robert F.
Herantis Pharma has reported new Phase 1b biomarker data that support the expected mechanism of action of HER-096, its…
GT-02287, an oral therapy being developed by Gain Therapeutics, was associated with improvements in motor function over three months…
Neuralight said a newly completed study showed its machine learning-based system monitoring eye movements via webcam is more sensitive…
Two proteins found on the surface of dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, may…
A new high-tech imaging tool that can “see” the toxic protein clumps thought responsible for Parkinson’s disease is heading into…
A new collaboration aims to accelerate the development of large-molecule therapeutics capable of entering the brain to treat neurological conditions,…
Zambon Biotech has dosed the first patient in its clinical trial testing Crexont (IPX203) — an extended-release formulation…
GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of…